Contrast Agent Applications

Hall C
Wednesday: 13:30 – 15:30

2019.   Comparison of Gd-DTPA BMA and NC100150 Enhancement Patterns in C3H Mammary Carcinoma Bearing Mice, L. Østergaard, P. Vestergaard-Poulsen, L. Bentzen, M.R. Horsman, J. Overgaard, A. Bjørnerud, K. Briley-Sæbø and C. Gyldensted, Aarhus University Hospital, Aarhus, Denmark and Nycomed/Amersham, Oslo, Norway.
2020.   Optimal dose of Gd-DTPA in Dynamic MR Studies, H. Rusinek, V. Lee, G. Johnson, A. Huang and A. Ton, NYU Medical Center, New York, NY, USA.
2021.   Quantification of Gadodiamide Signal Changes for rCBF Measurements, A. Tudorica, G.C. Newman, E. Delucia-Deranja, F.E. Hospod, W. Huang, C.S. Patlak and H.F. Li, State University of New York, Stony Brook, NY, USA.
2022.   Quantification of Gadodiamide Induced MR Signal Changes for Hemodynamic Measurements, A. Tudorica, G.C. Newman, E. Delucia-Deranja, F.E. Hospod, W. Huang, C.S. Patlak and H. Li, State University of New York, Stony Brook, NY, USA.
2023.   Quantitative Assessment of Gd-DTPA Contrast Agent from Signal Enhancement, M. Pedersen, J. Mørkenborg, F.T. Jensen, H. Stødkilde-Jørgensen and J. Frøkiær, Aarhus University Hospital, Aarhus, Denmark.
2024.   Human Cerebral Blood Flow Maps Improve with Higher Concentration of Contrast Agent, T. Benner, B. Tombach, J.P. Synnott, G. Schuierer, P. Reimer, V. Geens, L. Østergaard and A.G. Sorensen, Massachusetts General Hospital, Charlestown, MA, USA; Westfalian Wilhelms-University, Münster, Germany and Schering AG, Berlin, Germany.
2025.   Accurate De-Oxygenation of Ex Vivo Whole Blood Using Sodium Dithionite, K. Briley-Sæbø and A. Bjørnerud, Nycomed Imaging AS, Oslo, Norway.
2026.   Analytical Model of Susceptibility Induced MR Signal Dephasing By Capillaries, V.G. Kiselev and D.S. Novikov, Research Center Jülich GmbH, Jülich, Germany; Institute of Physics, Minsk, Byelorussia and California Institute of Technology, Pasadena, CA, USA.
2027.   An Estimate of the Error Introduced by ¹H Exchange in Bolus Tracking, G.R. Moran and F.S. Prato, The Lawson Research Institute, St. Joseph's Health Centre, London, Ontario, Canada.
2028.   The Effect of Equilibrium Transcytolemmal Water Exchange on the Determination of Contrast Reagent Concentration, [CR], C.S. Springer, Jr., C.S. Landis, X. Li and W.D. Rooney, Brookhaven National Laboratory, Upton, NY, USA and State University of New York, Stony Brook, NY, USA.
2029.   Comparison of Gadomer-17 and Gadopentetate dimeglumine (Gd-DTPA) for Assessment of Tumor Vascular Characterization, T. Motohara, K. Sugimura, Y. Ohno, T. Yoshikawa, M. Fujii, N. Katoh, T. Yokawa and H. Kitagaki, Shimane Medical University, Izumo, Japan; Kobe University, Kobe, Japan; Miki Civil Hospital, Miki, Japan and Nihon Schering, Osaka, Japan.
2030.   NC100150 Enhanced Imaging Offers the Possibility to Monitor Pharmacological Modification of Tumor Blood Flow and Blood Volume in Experimental Tumors in Mice, L. Bentzen, P. Vestergaard-Poulsen, M.R. Horsman, J. Overgaard, A. Bjørnerud, K. Briley-Sæbø, C. Gyldensted and L. Østergaard, Aarhus University Hospital, Aarhus, Denmark and Nycomed/Amersham Imaging, Oslo, Norway.
2031.   Determination of the Signal Intensity Time Course in Oxygen Enhanced MR Lung Imaging, C.J. Müller, M. Schwaiblmair, J. Scheidler, M. Deimling, J. Weber, C. Vogelmeier, R. Löffler and M. Reiser, Klinikum Großhadern, Ludwig-Maximilians-Universität, Munich, Germany and Siemens Medizintechnik, Erlangen, Germany.
2032.   Safety and Efficacy of Gadobenate Dimeglumine on MR Imaging of Pediatric CNS. Comparison with Gadopentatate Dimeglumine, A. La Noce, C. Baldoli, L. D'Incerti, I. Salerio, M.A. Kirchin, G. Pirovano and A. Spinazzi, Bracco SpA; Ospedale S. Raffaele and Instituto Neurologico Besta, Milan, Italy.
2033.   Comparison of the Contrasting Behaviour of Gd-BOPTA and Gd-DTPA for MR Imaging of CNS Tumors, M. Essig, M. Hartmann, F. Floemer, S. Heiland, H. Hawighorst, A. Mohr, O. Jansen, K-P. Lodemann and M.V. Knopp, German Cancer Research Center, Heidelberg, Germany and Bracco-Byk Gulden, Konstanz, Germany.
2034.   MRI Contrast Enhancement of Human Glioblastoma Multiforme with Gadolinium Texaphyrin, J.R. Alger, J.M. Ford, S. Haney, T.J. Endicott, D. Ludwig and A. Wagner, University of California, Los Angeles, CA, USA.
2035.   Contrast Enhanced MRI of Brain Tumor in Rats Using a New Medium Moledcular Size Contrast Agent NMS60 Compared with Low Molecular Size Gd-DTPA, Y. Hashiguchi, A. Nakatani, C. Fujimoto, S. Seri, K. Takahashi and M. Kato-Azuma, Nihon Medi-Physics Co. Ltd., Chiba, Japan.
2036.   Contrast Agent Enhanced 7T mMRI of a Transgenic Mouse Model of Multiple Sclerosis, Y. Zaim Wadghiri, L.A. Sheiman, J.J. Lafaille and D.H. Turnbull, NYU School of Medicine, New York, NY, USA.
2037.   Iron Oxide Black Blood Contrast Agent Improves Nerve Image Selectivity in MR Neurography, A.G. Filler, K.S. Tarlo, J.A. Haynes and P. Villablanca, UCLA Medical Center, Los Angeles, CA, USA and Nycomed, Wayne, PA, USA.
2038.   First Pass and Blood Pool Effect of a New Superparamagnetic Iron Oxide Blood Pool MR Contrast Agent: Phase I Clinical Trial, B. Tombach, P. Reimer, C. Bremer, T. Allkemper, M. Engelhardt, M. Mahler and W. Heindel, University of Muenster, Muenster, Germany and Schering AG, Berlin, Germany.
2039.   3D Fast MR Angiography of P 760 and Dose Effect Relationship After Intravenous Bolus Injection in Rabbit Compared to Gd-DOTA, R. Vosshenrich, E. Castillo, U. Fischer, B. Raab, C. Corot and E. Grabbe, Georg-August-Universität, Göttingen, Germany and Guerbet, Roissy, France.
2040.   3D-Micro-MR Angiography Using Macromolecular MR Contrast Agents with Various Size of Polyamidoamine Dendrimer Cores, H. Kobayashi, N. Sato, A. Hiraga, T. Saga, J. Konishi, K. Togashi and M.W. Brechbiel, Kyoto University, Kyoto, Japan and National Institutes of Health, Bethesda, MD, USA.
2041.   Value of Blood Pool Contrast Agent in Magnetic Resonance Venography (MRV) of the Lower Extremities and Pelvis, M. Aschauer, R. Stollberger, K.A. Hausegger, J. Raith, H. Portugaller, S. Doder and F. Ebner, University Hospital, Graz, Austria.
2042.   Interstitial MR Lymphography With MS-325 (Angiomark®), S.G. Ruehm, R. Lauffer, K. Treiber, A. Borowski and J.F. Debatin, University Hospital, Essen, Germany and EPIX Medical, Cambridge, MA, USA.
2043.   Superparamagnetic Iron Oxide MION: A Contrast Agent for ²³Na Cardiac MRI in Myocardial Infarction, C.D. Constantinides, D. Herzka, D. Bolar, F. Boada, D. Kraitchman, P.A. Bottomley and J. Rogers, Johns Hopkins University, Baltimore MD, USA; University of Pittsburgh, Pittsburgh, PA, USA and Advanced Magnetics Inc., Cambridge, MA, USA.
2044.   Assessment of Myocardial Viability in Hyperenhanced Moderately Injured Myocardium Using
Gd-DTPA and Gadophrin,
M. Saeed, G. Lund, M.F. Wendland, J. Bremerich, H-J. Weinmann and C.B. Higgins, University of California, San Francisco, CA, USA and Schering AG, Berlin, Germany.
2045.   Occlusive Myocardial Infarction: Investigation of Gadophrin-2 Enhanced MR Imaging in a Cat Model, S.S. Lee, S.H. Choi, S.I. Choi, S.T. Kim, K.H. Lim, C.H. Lim and T-H. Lim, Asan Medical Center, University of Ulsan College of Medicine and Asan Institute for Life Sciences, Seoul, Korea.
2046.   Assessment of Myocardial Viability with Use of Necrosis-Avid Versus Blood Pool MR Contrast Agents in Reperfused Myocardial Infarction in a Cat Model, D.H. Kim, S.I. Choi, S.T. Kim, K.H. Lim, C.H. Lim, G.Y. Gong, H-J. Weinmann and T-H. Lim, Asan Medical Center, University of Ulsan College of Medicine and Asan Institute for Life Sciences, Seoul, Korea and Schering AG, Berlin, Germany.
2047.   EVP 1001-1: A New Cardiac Specific MR Contrast Agent with Optimal Kinetics for Evaluation of the Ischemic Heart, P.R. Seoane, P.V. Prasad, R.R. Edelman and P.P. Harnish, Eagle Vision Pharmaceutical Corp., Chester Springs, PA, USA and Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
2048.   Morphological and Functional MR Imaging of Focal Nodular Hyperplasia with Gadobenate Dimeglumine: Work in Progress, G. Morana, L. Grazioli, M. Kirchin, A. Spinazzi, A. Chiesa and C. Procacci, University of Verona, Verona, Italy; University of Brescia, Brescia, Italy and Bracco SpA, Milan, Italy.
2049.   The Rim Enhancement Patterns of Liver-Specific Gd-EOB-DTPA and MnDPDP in Hepatic Abscess Model, Y. Chang, H.J. Park, J.M. Lee, B.S. Han and D.S. Kang, Kyungpook National University, Taegu, Korea.
2050.   Low-Dose Gadobenate Dimeglumine-Enhanced MRI in the Detection and Charcterization of Focal Liver Lesions, G. Pirovano, M. Kirchin and A. Spinazzi, Bracco S.p.A., Milan, Italy.
2051.   Optimal Delay Time for MR Imaging of the Biliary Tract Following Mn-DPDP Administration, G.S. Foster and D. Hebel, Rush University, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.
2052.   Gadobenate Dimeglumine-enhanced Dynamic Imaging of Hypervascular Liver Lesions in Previously Contrast-Enhanced Liver Parenchyma, G. Schneider, K. Altmeyer, M. Kirchin, R. Seidel, A. Stumm and B. Kramann, University Hospital, Homburg / Saar, Germany.
2053.   MRI Detection of Macrophage Infiltration in Rat Renal Transplantation, C. Ho, Y. Zhang, S.J. Dodd, K.S. Hendrich and M. Williams, Carnegie Mellon University, Pittsburgh, PA, USA.
2054.   Excretion of Gadopentetate Dimeglumine into Human Breast Milk During Lactation, R.A. Kubik-Huch, N.M. Gottstein-Aalame, T. Frenzel, B. Seifert, E. Puchert and J.F. Debatin, University Hospital, Zurich, Switzerland; Schering AG, Berlin, Germany and University of Zurich, Zurich, Switzerland.

Return to ISMRM program